Table 3.
Univariate and multivariable analyses of overall survival.
| UVA | MVA | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p | HR | 95% CI | p | |
| Age (years) | 1.06 | 0.96–1.16 | 0.259 | |||
| Sex (male vs. female) | 0.45 | 0.21–0.97 | 0.042 | 1.51 | 0.61–3.69 | 0.371 |
| ECOG (0 vs. 1–2) | 0.99 | 0.45–2.20 | 0.981 | |||
| ACE-27 (0–1 vs. 2–3) | 0.35 | 0.16–0.74 | 0.007 | 0.82 | 0.28–2.39 | 0.722 |
| Disease extent (BRPC vs. LAPC) | 1.36 | 0.66–2.81 | 0.403 | |||
| Tumor location (head vs. other) | 0.66 | 0.32–1.35 | 0.256 | |||
| Induction CT duration (>4 vs. ≤4 months) | 0.63 | 0.29–1.34 | 0.229 | |||
| Induction CT (mFFX vs. GnP) | 1.29 | 0.60–2.76 | 0.516 | |||
| Resected (yes vs. no) | 0.20 | 0.092–0.42 | <0.001 | 0.30 | 0.12–0.91 | 0.031 |
| Baseline CA 19-9 (U/mL) | 0.99 | 0.99–1.00 | 0.883 | |||
| Pre-SBRT CA 19-9 (U/mL) | 1.00 | 0.99–1.00 | 0.633 | |||
| Baseline Total Bilirubin (mg/dL) | 1.00 | 0.88–1.10 | 0.989 | |||
| Post-SBRT/surgery chemotherapy (yes vs. no) | 0.26 | 0.11–0.64 | 0.004 | 0.41 | 0.15–1.14 | 0.087 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ACE-27, adult comorbidity evaluation-27; BRPC, borderline resectable pancreatic cancer; LAPC, locally advanced pancreatic cancer; mFFX, modified FOLFIRINOX; GnP, gemcitabine plus nab-paclitaxel; CA 19-9, cancer antigen 19-9; SBRT, stereotactic body radiation therapy. Bold text indicates p-value < 0.05.